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Abstract Interlaboratory variation in human epidermal
growth factor receptor 2 (HER2) testing provides a
challenge for targeted therapy in breast and gastric cancer.
Assessment of positivity rates among laboratories could
help monitor their performance and define reference values
for positivity rates to be expected in a geographic region.
Pathologists regularly determined the number of HER2-
positive cases (HER2 3+, HER2 2+/amplified or amplified)
in their laboratory, and figures were continuously entered
into a central website. The overall positivity rate of each
participant was calculated and compared with the average
rates of all other institutes (n=42). A total of 18,081 test
results on breast cancer and 982 on gastric cancer were
entered into the system. Positivity rates for HER2 in breast
cancer ranged from 7.6% to 31.6%. Statistically, the results
from six institutions qualified as outliers (p<0.000005).
From the remaining institutions encompassing 10,916
assessments, the mean proportion of positive cases was
16.7±3.2% (99% confidence interval 16.6–16.8). The
results from six institutions were in between the 95% and
99.5% confidence intervals. For gastric cancer, there was
one outlier and the mean positivity rate was 23.2±5.7%.
The proportion of HER2-positive breast cancer cases is
considerably lower than could have been expected from
published studies. By assessing the positivity rates and
comparing them with that of all breast or gastric cancers in
a given population, pathologists will be alerted to a
potential systematic error in their laboratory assay, causa-
tive for over- or underestimation of cancer cases suited for
anti-HER2 therapy.
Keywords HER2.Breast cancer.Gastric cancer.Quality
assurance.Predictive pathology
Introduction
Targeted therapy against human epidermal growth factor
receptor 2 (HER2)-overexpressing tumours provides a
major breakthrough in cancer therapy [1]. The identification
of cancer patients who are suited for anti-HER2 therapy
depends on the analysis of cancer tissue by immunohisto-
chemistry (IH) or in situ hybridisation (ISH), which usually
is performed by pathology departments. Central retesting
within the framework of therapy trials has revealed
considerable interlaboratory variation [2–4]. Testing inac-
curacy was identified as a major issue with either assay, IH
and ISH [5]. Proficiency testing by round robin tests was
launched in several countries as a potential remedy [6–10].
Although useful and indispensable, proficiency testing
surveys render only an incomplete and ephemeral assess-
ment of testing performance and do not necessarily reflect
the lasting reliability. Furthermore, they rely on artificial
systems such as tissue microarrays or cell lines [9, 10].
Usually, they do not cover the whole process and omit
decisive steps such as tissue fixation and processing [11].
From regular proficiency tests, it became obvious that
inaccurate results were not haphazardly distributed but
followed a systematic trait [7, 8]. Participating pathologists
who were unsuccessful in most instances failed either
because of systematic false-positive or false-negative
staining [8]. In a central review of 1,459 cases from
Germany in an international therapy trial and tested locally
as HER2 3+, only 1,167 could be confirmed by central
testing (80%) (results not published). The 1,459 cases were
derived from 116 different centres, from which a small
number (6%) were responsible for 23% of discrepant cases
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data). These observations led us to the conclusion that
surveillance of positivity rat e si nH E R 2t e s t i n gm a yh e l p
identify laboratories with insufficient testing assays and a
high yield of false-positive or negative results. Conse-
quently, pathologists were offered the opportunity to
compare their positivity rates with those of others in
Germany, Austria and Switzerland. Because German
guidelines require that every case of invasive breast
cancer is tested for HER2, there are more than 40,000
H E R 2t e s t so fb r e a s tc a n c e ri nG e r m a n yp e ry e a r[ 12].
From published results, it is difficult to calculate the
proportion of positive cases to be expected when optimal
testing circumstances are present. Initial studies suggested
overexpression in as many as 30% of cases [13]. Larger
series recently revealed lower positivity rates with either
ISH or IH ranging from 18% to 22.7% [14, 15]. Therefore,
a second aim of the study was to obtain an estimate of the
positivity rate which has to be expected among a
population of breast and gastric cancers in central Europe.
Material and methods
In 2010, all pathology departments in Germany, Austria and
Switzerland were offered the opportunity by the German
Society of Pathology and the Association of German
Pathologists to enter their positivity rates for HER2 testing
on breast and gastric cancer into a central web page.
Institutes willing to participate received an access code to
guarantee confidentiality. The individual figures could be
entered on a weekly or monthly basis. The figures which
were entered comprised the number of cases being HER2 0;
HER2 1+; HER2 2+; HER2 2+; and amplified in ISH,
HER2 3+. For those laboratories which only perform ISH,
the numbers for cases not amplified or amplified or falling
into the equivocal grey zone [5] were entered.
The average positivity rates of all other institutes
corrected for the number of cases entered into the survey
were compared to the individual result. A system of traffic
lights was indicated to institutes whether they lay outside
the 95% confidence interval (yellow) or the 99.5%
confidence interval (red).
Statistics
Differences between institutions were analysed by using the
χ
2 test. Before determining the rate of HER2-positive
cases, the data were checked for outliers. The data from
every institution were compared to the pooled data from the
other institutions, and the data from those institutions
differing highly significantly from the other institutions
(p<0.0005) were excluded in a stepwise manner. The
exclusion procedure was stopped when none of the
remaining institutions differed highly significantly (p<
0.0005) from the pooled data of the other laboratories that
had not been excluded. Institutions excluded by this
procedure were regarded as outliers and therefore not taken
into consideration when determining the rate of HER2-
positive cases.
On the basis of the rate of HER2-positive cases
determined by the results from the laboratories not
excluded as outliers, 95% and 99.5% confidence intervals
were calculated for the number of HER2-positive cases
applying the binomial distribution for n≤500 and approx-
imating the binomial distribution by the normal distribution
for n>500.
Results
Within 1 year, 42 institutes of pathology (9 in academic
institutions, 17 in community hospitals and 16 in private
praxis) entered the results of their HER2 testing in breast
cancer into the system. Test results on 18,081 breast cancers
were communicated. The average number of cases per
institute was 430.5 ranging from 4 to 2,733 cases. Seven
institutes entered results of fewer than 50 cases of breast
cancer. With regard to gastric cancer, 3 institutions
communicated more than 50 assessments during the period
under study. Positivity rates for HER2 in breast cancer
ranged from 7.6% to 31.6%. The average positivity rate of
all 42 institutes corrected for the number of cases was
14.61±4.55%. In order to exclude regional differences, the
data were screened for potential association with postal
codes, which turned out not to be the case (data not shown).
Statistically, the results from six institutions were consid-
ered to be outliers (p<0.000005). Therefore, the results of
these institutes were not included when the expected rate of
HER2-positive cases per institute and the number of assays
were determined. Of the remaining 10,916 assessments, the
mean proportion of positive cases was 16.7% (99%
confidence interval 16.6–16.8). Six institutions were out-
side of the 99.5% confidence interval (Fig. 1). The number
of HER2 assessments performed by the institutes outside
the 99.5% confidence interval ranged from 189 to 3,287
cases. There were two institutes outside the 99.5%
confidence interval which had entered more than 2,500
cases. Two institutes assessed HER2 exclusively by in situ
hybridisation and did not rely on immunohistochemistry.
One of these institutions had performed 491 assessments
and proved to be outside the 99.5% confidence interval
with 8.35% unequivocally amplified cases.
Of the remaining 36 participating institutes, 6 institutions
were in between the 95% and 99.5% confidence interval
(p<0.0005) (Fig. 1). All of these institutions had commu-
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cases. No correlation to the type of institute (academic,
community hospital or private praxis) could be observed.
The proportion of cases tested immunohistochemically
as HER2 2+ ranged from 0% to 60.1% of all assessments
(mean 16.5±15.5%). With regard to the 36 reference
institutes within the 99.5% confidence interval, the mean
percentage of HER2 2+ cases was 18.7±14.0% (Table 1).
Of the HER2 cases which were further analysed by in situ
hybridisation, 17.9±17.0% were amplified (range 0.0–
75.0%) (Table 1). Two of the six institutes outside the
99.5% confidence interval rendered a HER2 2+ assess-
ment on 2.8% and 7.6% of cases, respectively. Institutes,
which had lower numbers of HER2-positive cases, also
revealed a low percentage of 2+ assessments. There was a
highly significant correlation between low HER2 positivity
rates and low proportion of cases within the 2+ category
(p<0.000005).
With regard to gastric cancer, 15 institutes of pathology
took part and entered 982 results of their assays. The
average positivity rate was 24.11±7.35%. After correction
for one outlier, the mean positivity rate was 23.2±5.7%
(Table 1). Because the number of cases per institute was
rather small, there was a broad range of positivity rates
which fell into the 99.5% confidence interval (Fig. 2). Of
the 15 participating institutes, only one institute was outside
the 99.5% confidence interval and none further outside the
95% interval (Fig. 2). The percentage of cases tested as
HER2 2+ was 28.7±12.7% (range 0.0–71.4%). Of these,
30.5±12.1% were amplified by in situ hybridisation (range
0–52.2%) (Table 1).
Discussion
HER2 testing provides the prototype of a new field in
pathology, which has been termed predictive pathology. The
results of clinical trials demonstrated a significant benefit of
HER2-targeted therapy for early and late stages of breast
cancer [1, 16] as well as recently also for gastric cancer [17].
Interlaboratory variation in HER2 testing became obvious
from trials with central re-testing [3, 4]. Although regular
participation in proficiency testing significantly improved the
performance of individual institutes [8], there are doubts that
the current quality assurance methods are sufficient to reduce
testing variation. In order to improve the reliability of testing,
several efforts have been undertaken. Guideline recommen-
dations have been published which set standards for thresh-
olds between positive and negative HER2 test results
and define algorithms [5, 18]. Furthermore, regular and
predominantly tissue microarray-based proficiency tests
are organised in Europe and USA [6, 9, 10].
Fig. 1 The number of HER2-positive breast cancer cases (HER2 3+,
HER2 2+/amplified, amplified) per institute of pathology in relation to
the number of cases investigated was plotted on a logarithmic scale.
The 99.5% confidence interval is indicated by red lines. In institutions
with a low number of assessments, the confidence interval is broader.
The expected rate calculated from the mean value of 36 institutions
within the 99.5% confidence interval is demonstrated by a blue line.
There are six institutions outside the 99.5% confidence interval
(indicated by red crosses). Four of these potentially underestimate
HER2 and two have a higher positivity rate than could have been
expected. Institutes with a positivity rate within the 99.5% confidence
interval are represented by white circles
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not reflect the permanent accuracy of HER2 assessment in
routine practice. An auxiliary instrument to compensate for
this limitation and to assure quality of HER2 testing is
presented here. By monitoring positivity rates in HER2
testing, institutes of pathology were identified, which lay
outside the 99.5% confidence interval of expected results.
The exact frequency of HER2-overexpressing or amplified
cancers was not known and had to be determined in order
to define a reference value. The positivity rates reported in
the literature range from 18% to 30% [13–15]. On the basis
of 10,916 assessments in 36 institutes of pathology, a mean
positivity rate of 16.7% was determined (Table 1). Because
HER2 testing is performed on every breast cancer in
Germany, there is no selection bias in this study as might
be the case in therapy trials. Six institutes were outside of
the 99.5% confidence interval (Fig. 1). These outliers were
informed that a systematic error in the methodology of
HER2 assessment in their laboratory might cause over- or
underestimation of HER2 in cancer. Of the six institutes
Table 1 HER2 positivity rates in breast and gastric cancer
Breast cancer Gastric cancer
Number of HER2 assay results 18,081 982
Participating institutes of pathology 42 15
Average HER2 assay number per institute±standard deviation 430±705 65±118
Mean HER2 positivity rate
a±standard deviation 16.7±3.2% 23.2±5.7%
Range
a 11.8–23.1% 17.6–28.1%
Outliers 6 (14.3%) 1 (6.7%)
HER2 2+ (mean rate
a±standard deviation) 18.7±14.0% 28.7±12.7%
Range
a 0.0–54.0% 13.9–54.6%
HER2 gene amplification rate among HER2 2+ cases 17.9±17.0% 30.5±12.1%
Range
a 0.0–75.0% 8.3–52.2%
aInstitutes with outlying positivity rates were not included in the calculation of the mean value and range; institutes with ≤20 gastric cancer cases
and <35 breast cancer cases were merged and considered as a single group
Fig. 2 The number of HER2-positive gastric cancer cases (HER2 3+,
HER2 2+/amplified) per institute of pathology in relation to the
number of cases investigated was plotted on a logarithmic scale. The
99.5% confidence interval is indicated by red lines. In institutions with
a low number of assessments, the confidence interval is broader. The
expected rate calculated from the mean value of 14 institutions within
the 99.5% confidence interval is demonstrated by a blue line. There is
one institution outside the 99.5% confidence interval (indicated by a
black cross). Institutes with a positivity rate within the 99.5%
confidence interval are represented by black points. The confidence
interval might narrow over time when more assessments are available
for consideration
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participated in round robin tests on HER2 assessment offered
in Germany. Three of the institutes with low positivity rates
had received the information that the sensitivity of their
detectionmethodmightbetoolowinatleastoneoftheannual
quality assurance trials. Interestingly, a high frequency of
assessments did not protect from potential systematic errors.
Two institutes which revealed positivity rates outside the
99.5% confidence interval had entered more than 2,500 cases
(Fig. 1). It remains to be determined by further studies
whether the traffic light system is efficient in improving
HER2 assessments in underperforming institutes.
Diversity of positivity rates was highest when the HER2
2+ category was considered (Table 1). This finding
indicates that the HER2 2+ category might be limited by
subjectivity and poor reproducibility [19] (Fig. 3). In a
recent meta-analysis on 17 studies encompassing 8,410
patients, the mean proportion of the HER2 2+ category was
23.2% with a broad range from 2.0% to 87.5% [20]. Only a
slight enrichment for amplified cases was found (26.5% vs.
21.1%) [20]. When compared with ISH results in this study,
there was no significant enrichment of amplified cases in
the HER2 2+ group (Table 1).
Institutes which rely completely on ISH instead of IH to
assess HER2 positivity were too few to allow for
comparison (Fig. 3). Whether ISH or IH is more reliable
and reproducible is a matter of debate [19]. In this study,
one of the two institutes which exclusively performed ISH
was outside the 99.5% confidence interval.
In order to keep the entering of data into the HER2
monitor as simple as possible and not to reduce the
compliance of participants, no detailed information on
methods or composition of cases was requested from the
participants. It cannot be excluded that an abnormal
proportion of low-grade cancers or other specific conditions
may be responsible for an aberrant positivity rate. There-
fore, a positivity rate outside the 99.5% confidence interval
does not necessarily imply that the HER2 assessment
method in use is inadequate. Such a finding should,
however, urge pathologists to consider this possibility. The
primary aim of monitoring HER2 positivity rates is to alert
institutes of pathology to potential systematic errors which
require further measures to assure quality of testing. As a
consequence of abnormal positivity rates, tests in use could
be validated or participation in proficiency tests could take
place with higher frequency. Only if methodological
problems have been excluded should secondary influences
such as abnormal composition of the set of samples in
which HER2 has been assessed be taken into consideration.
Two institutes with a high number of tests and a low positivity
rate outside the 99.5% confidence interval also documented
extremely low HER2 2+ rates. Unlike the 3+ category, the 2+
category is not related to histological grade. Therefore, it
appears highly unlikely that in these two institutes, which
together performed more than 6,000 HER2 assessments in
breast cancer, a selection bias towards grade 1 and 2 cases
might be responsible for the low total positivity rate.
Most therapy trials on targeted HER2 therapy require
central retesting of samples which were locally assessed as
HER2 positive. As a consequence, central retesting in trials
alerts pathologists to false-positive but not to false-negative
assessments. This inherent tendency might explain why
there are twice as many institutes which potentially
underestimate HER2 positivity than institutes with potential
overestimation (n=4; 99.5% confidence interval). Thus,
without eliminating outliers, the mean rate of HER2-
Fig. 3 A high degree of vari-
ability between institutes was
observed with regard to the
HER2 2+ category. In particular,
the differentiation between
HER2 2+ and HER2 1+ might
be handled differently. This case
illustrates the borderline
between the 2+ category (intra-
ductal carcinoma, double arrow)
and the 1+ category (invasive
carcinoma, single arrow)
(immunohistochemistry with
4B5 anti-HER2 monoclonal
antibody, ×200)
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cancers). An almost identical rate was found by question-
naires on 4,940 breast cancer samples in Sweden [21] and
slightly higher in Australia (17.1%, 6,512 cases) [22]. In
contrast to the HER2 monitor presented here, in both
studies, outliers had not been eliminated from the calcula-
tion of the expected positivity rate.
There are several measures which institutes of pathology
can take to assure quality of HER2 testing. Besides on-slide
controls [23], participation in proficiency tests and adher-
ence to guidelines [5–10, 18, 24], a further instrument is
proposed here. Monitoring of positivity rates and compar-
ison with an expected value will help identify potential
errors in HER2 assessment, which lead to systematic over-
or underestimation of HER2 in cancer.
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